🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 29/01/2009 | 32,30 | 33,98 | 32,19 | 33,72 | +3,63% | 5,54% | 2.793.000 |
| 28/01/2009 | 31,59 | 32,99 | 31,44 | 32,54 | +2,84% | 4,91% | 1.371.600 |
| 27/01/2009 | 31,56 | 31,89 | 31,03 | 31,64 | +0,67% | 2,72% | 1.800.700 |
| 26/01/2009 | 31,01 | 32,13 | 31,01 | 31,43 | +1,58% | 3,61% | 1.427.900 |
| 23/01/2009 | 30,45 | 31,70 | 30,27 | 30,94 | -0,13% | 4,70% | 1.103.900 |
| 22/01/2009 | 30,76 | 31,75 | 30,50 | 30,98 | -1,74% | 4,06% | 1.387.700 |
| 21/01/2009 | 29,91 | 31,60 | 29,78 | 31,53 | +6,95% | 6,08% | 2.656.600 |
| 20/01/2009 | 30,84 | 31,99 | 29,38 | 29,48 | -4,13% | 8,46% | 2.449.600 |
| 16/01/2009 | 31,00 | 31,36 | 30,07 | 30,75 | -0,36% | 4,16% | 2.045.700 |
| 15/01/2009 | 30,11 | 31,10 | 29,17 | 30,86 | +2,76% | 6,41% | 1.626.200 |
| 14/01/2009 | 30,76 | 31,54 | 29,85 | 30,03 | -3,84% | 5,49% | 1.726.200 |
| 13/01/2009 | 29,62 | 31,72 | 29,33 | 31,23 | +5,79% | 8,07% | 2.139.700 |
| 12/01/2009 | 30,04 | 30,30 | 28,86 | 29,52 | -1,30% | 4,79% | 1.549.800 |
| 09/01/2009 | 31,85 | 31,85 | 29,50 | 29,91 | -5,85% | 7,38% | 1.752.800 |
| 08/01/2009 | 31,46 | 31,77 | 30,33 | 31,77 | +0,79% | 4,58% | 1.867.600 |
| 07/01/2009 | 31,21 | 31,85 | 30,78 | 31,52 | -0,35% | 3,43% | 1.703.300 |
| 06/01/2009 | 31,92 | 32,65 | 30,75 | 31,63 | -1,62% | 5,95% | 2.055.600 |
| 05/01/2009 | 30,63 | 32,27 | 30,24 | 32,15 | +4,76% | 6,63% | 2.331.600 |
| 02/01/2009 | 30,27 | 30,73 | 29,57 | 30,69 | +1,02% | 3,83% | 1.216.600 |
| 31/12/2008 | 30,50 | 30,97 | 29,85 | 30,38 | -0,10% | 3,67% | 1.166.500 |
| 30/12/2008 | 28,98 | 30,47 | 28,52 | 30,41 | +5,77% | 6,73% | 1.302.400 |
| 29/12/2008 | 29,26 | 29,50 | 28,05 | 28,75 | -2,54% | 4,96% | 717.000 |
| 26/12/2008 | 29,24 | 29,58 | 28,68 | 29,50 | +1,76% | 3,08% | 433.200 |
| 24/12/2008 | 29,04 | 29,41 | 28,60 | 28,99 | -0,62% | 2,79% | 279.500 |
| 23/12/2008 | 28,98 | 29,60 | 28,78 | 29,17 | +1,04% | 2,83% | 1.012.100 |
| 22/12/2008 | 29,74 | 29,94 | 27,98 | 28,87 | -3,19% | 6,59% | 1.308.400 |
| 19/12/2008 | 29,61 | 30,45 | 29,16 | 29,82 | +2,26% | 4,36% | 2.856.600 |
| 18/12/2008 | 28,25 | 29,16 | 27,91 | 29,16 | +5,50% | 4,42% | 2.246.200 |
| 17/12/2008 | 27,23 | 28,58 | 27,05 | 27,64 | -1,18% | 5,62% | 2.516.000 |
| 16/12/2008 | 25,50 | 28,00 | 25,16 | 27,97 | +11,12% | 11,14% | 1.833.200 |